These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7579490)

  • 41. The histologic spectrum of apocrine breast proliferations: a comparative study of morphology and DNA content by image analysis.
    Raju U; Zarbo RJ; Kubus J; Schultz DS
    Hum Pathol; 1993 Feb; 24(2):173-81. PubMed ID: 8381766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Value of cytometric analysis for distinction of intraductal carcinoma of the breast.
    Fisher ER; Siderits R
    Breast Cancer Res Treat; 1992; 21(3):165-72. PubMed ID: 1325216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting.
    Hanna WM; Kahn HJ; Pienkowska M; Blondal J; Seth A; Marks A
    Mod Pathol; 2001 Jul; 14(7):677-85. PubMed ID: 11455000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
    Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S; Staff S; Tanner M; Isola J
    Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The level of phosphorylated Akt predominantly reflects the expressive status of CerbB2 in invasive breast cancer.
    Chi Y; Zhao J; Cui SP; Jiang P; Wang HL; Zhang H; Mao JZ; Liu HJ; Hou L; Zhang B
    Histol Histopathol; 2013 May; 28(5):655-61. PubMed ID: 23420345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
    Poller DN; Snead DR; Roberts EC; Galea M; Bell JA; Gilmour A; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1993 Jul; 68(1):156-61. PubMed ID: 8100443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA ploidy in intraductal breast carcinomas.
    Aasmundstad TA; Haugen OA
    Eur J Cancer; 1990; 26(9):956-9. PubMed ID: 2177615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Establishing a cytogenetic and morphological progression models of invasive breast cancer. Comparative genomic hybridization (CGH) in malignant and premalignant tumors of the female breast].
    Bürger H; Poremba C; Diallo R; Dockhorn-Dworniczak B; Böcker W
    Pathologe; 2000 Sep; 21(5):375-82. PubMed ID: 11092010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNA analysis of ductal carcinoma in situ of the breast. A comparison with histologic features.
    Killeen JL; Namiki H
    Cancer; 1991 Dec; 68(12):2602-7. PubMed ID: 1657363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas.
    Angèle S; Treilleux I; Brémond A; Tanière P; Hall J
    Histopathology; 2003 Oct; 43(4):347-53. PubMed ID: 14511253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein.
    Poller DN; Roberts EC; Bell JA; Elston CW; Blamey RW; Ellis IO
    Hum Pathol; 1993 May; 24(5):463-8. PubMed ID: 8098318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast.
    Crissman JD; Visscher DW; Kubus J
    Arch Pathol Lab Med; 1990 Dec; 114(12):1249-53. PubMed ID: 2174672
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland.
    Bradbury JM; Arno J; Edwards PA
    Oncogene; 1993 Jun; 8(6):1551-8. PubMed ID: 8099220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.
    Volinia S; Galasso M; Sana ME; Wise TF; Palatini J; Huebner K; Croce CM
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3024-9. PubMed ID: 22315424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
    Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
    Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
    Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
    Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.